Up to 55% of patients developed anti-drug antibodies [65], which were associated with systemic allergic reactions in approximately 5% of cases and injection-site hypersensitivity, including anaphylaxis, which necessitated early trial termination [66, 67]
Notably, over the subsequent 6 days, we observed a sustained body-weight-lowering effect after infusion of GLP-1MK-801, but not semaglutide, suggesting that the targeted inhibition of NMDA receptors in GLP-1 receptor-positive neurons might promote sustained changes to the defended level of adiposity
The setup
GLP-1 lawsuit claims center on allegations that manufacturers of medications such as Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 receptor agonist drugs failed to adequately warn patients and physicians about serious health risks associated with these medications
A 14 mg semaglutide pill form was associated with more weight loss than the injectable GLP-1s lixisenatide (which is no longer on the market in the United States) and exenatide
